Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Study of Sodium Thiosulfate Injections for Patients with Ectopic Calcifications or Ossifications from Dermatomyositis, Systemic Sclerosis, or iPPSD2

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment for certain types of abnormal tissue growths in the body. These growths are known as ectopic calcifications and ectopic ossifications. The trial is specifically looking at these conditions when they occur due to three diseases: dermatomyositis, systemic sclerosis, and a rare condition called iPPSD2. The treatment being tested is a solution called sodium thiosulfate, which is given as an injection under the skin.

The purpose of the study is to see how effective sodium thiosulfate is in reducing these abnormal growths over a period of six months. Participants will first go through a six-month observation period, followed by six months of receiving the treatment. During this time, the size of the growths will be monitored using imaging techniques, and any changes in pain or quality of life will also be assessed.

This study aims to provide valuable information on whether sodium thiosulfate can help manage these conditions and improve the lives of those affected by them. Participants will be closely monitored for any side effects or changes in their condition throughout the study period.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    The trial begins with an initial assessment to confirm eligibility. This includes a review of medical history and current health status.

    Eligibility is based on the presence of ectopic calcification or ossification due to specific conditions such as dermatomyositis, systemic sclerosis, or iPPSD2.

  2. Step 2

    Run-in period

    A run-in period of 6 months is conducted before the main treatment phase. During this time, no active treatment is administered.

    This period is used to establish baseline measurements of the calcifications or ossifications using CT scans.

  3. Step 3

    Treatment phase

    The treatment phase lasts for 6 months, during which a 10% solution of sodium thiosulfate is injected subcutaneously.

    The injections are administered locally to the affected areas to evaluate their effect on the calcifications or ossifications.

  4. Step 4

    Monitoring and evaluation

    Throughout the treatment phase, regular monitoring is conducted to assess the volume of calcifications or ossifications using CT scans.

    Additional evaluations include monitoring for any adverse events, changes in bone density, and pain levels associated with the treatment.

  5. Step 5

    Final assessment

    At the end of the treatment phase, a final assessment is conducted to measure the percentage change in the volume of calcifications or ossifications.

    The final assessment also includes evaluations of pain and quality of life to determine the overall impact of the treatment.

Who can join the trial?

7 criteria

  • The patient must have **ectopic calcification** (abnormal calcium deposits in the body) due to **dermatomyositis** (a condition causing skin and muscle inflammation) or **systemic sclerosis** (a disease causing hardening of the skin and connective tissues) and be 18 years or older.
  • Alternatively, the patient can have **ectopic ossification** (abnormal bone formation) due to **iPPSD2** (a specific genetic condition) and be between 2 and 30 years old.
  • The need for **STS infusion** (a treatment involving a specific solution) must be confirmed by a group of medical experts, based on the significant health impact of the calcification or ossification.
  • The patient should not have any planned surgery for the calcifications or ossifications in the next 12 months.
  • Women who can have children must use highly effective birth control methods, such as hormonal contraception, an intrauterine device, or other reliable methods, during the study and for one month after the last injection. Men with partners who can have children should use condoms during the study and for 91 days after the last injection.
  • The patient or their parents must sign a form agreeing to participate in the study.
  • The patient must be part of or have benefits from the social security system.

Who cannot join the trial?

9 criteria

  • Patients who have a different condition than those specified, such as ectopic ossification or ectopic calcification due to other causes.
  • Patients who are not within the specified age range for the study.
  • Patients who are not able to give informed consent or understand the study requirements.
  • Patients who are pregnant or breastfeeding.
  • Patients who have a history of allergic reactions to the treatment being tested.
  • Patients who are currently participating in another clinical trial.
  • Patients with severe health conditions that could interfere with the study.
  • Patients who have had recent surgery or are planning to have surgery during the study period.
  • Patients who are unable to comply with the study procedures and visits.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Sodium Thiosulfate: This medication is used in the trial to treat abnormal calcium deposits in the body, known as calcifications, and unwanted bone growths, known as ossifications. It is administered through subcutaneous injections, which means it is injected under the skin. The study aims to see how effective this treatment is over a period of six months for conditions like dermatomyositis, systemic sclerosis, and iPPSD2.

What is already known about the treatment

Sodium Thiosulfate – This medication is administered through subcutaneous injections, meaning it is injected under the skin. It is currently being studied in clinical trials for its effectiveness in treating ectopic calcifications and ossifications, which are abnormal deposits of calcium in tissues. The main therapeutic indications include conditions like dermatomyositis, systemic sclerosis, and iPPSD2, where such calcifications occur. Sodium Thiosulfate works by dissolving calcium deposits at the molecular level, helping to reduce these abnormal accumulations. It is classified pharmacologically as a chelating agent, which means it binds to minerals and metals, aiding in their removal from the body.

Investigated diseases

  • Dermatomyositis

    Dermatomyositis is an inflammatory disease characterized by muscle weakness and a distinctive skin rash. The condition often begins with a violet or dusky red rash, typically on the face, eyelids, knuckles, elbows, knees, chest, and back. Muscle weakness usually affects the muscles closest to the trunk, such as those in the hips, thighs, shoulders, and neck. Over time, the weakness can make it difficult to climb stairs, lift objects, or even rise from a seated position. The disease can also cause joint pain, fatigue, and difficulty swallowing. In some cases, calcifications can form in the skin and muscles, leading to further complications.

  • Systemic Sclerosis

    Systemic sclerosis, also known as scleroderma, is a chronic connective tissue disease characterized by changes in the skin, blood vessels, muscles, and internal organs. The disease often begins with skin thickening and hardening, particularly on the hands and face. Over time, it can lead to restricted movement and joint pain. Systemic sclerosis can also affect internal organs, such as the lungs, heart, and kidneys, leading to a range of symptoms depending on the organs involved. The condition may cause calcifications in the skin and other tissues, contributing to stiffness and discomfort. The progression and severity of symptoms can vary widely among individuals.

  • iPPSD2

    iPPSD2, or idiopathic progressive pseudorheumatoid dysplasia type 2, is a rare genetic disorder that affects bone and joint development. It is characterized by progressive joint stiffness, pain, and swelling, often beginning in childhood. The condition can lead to a decrease in joint mobility and may cause deformities over time. Ectopic ossification, or abnormal bone formation in soft tissues, is a common feature of iPPSD2. This can result in additional stiffness and discomfort, impacting daily activities. The progression of symptoms can vary, with some individuals experiencing more severe effects than others.

Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-511620-13-00Protocol codeI17004Estimated enrolment40 patientsSponsorCentre Hospitalier Et Universitaire De Limoges

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.